Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Clinical Trial ID NCT00638690

PubWeight™ 93.10‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00638690

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011 27.58
2 Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012 6.49
3 Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010 5.86
4 Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol 2015 5.48
5 Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010 4.64
6 Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012 3.82
7 Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol 2013 2.57
8 Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011 2.17
9 New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 2011 2.01
10 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
11 Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2010 1.86
12 Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur Urol 2013 1.74
13 CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol 2010 1.70
14 Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010 1.67
15 Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. Clin Cancer Res 2015 1.55
16 The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 2011 1.55
17 Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J 2011 1.25
18 Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2013 1.22
19 Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2009 1.04
20 Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J 2011 1.04
21 Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther 2010 1.00
22 Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer 2013 0.98
23 Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging 2010 0.96
24 Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets 2012 0.95
25 A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol 2015 0.91
26 Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist 2011 0.90
27 Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol 2012 0.89
28 Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer? Nat Clin Pract Oncol 2008 0.88
29 Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One 2012 0.88
30 Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis 2014 0.86
31 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
32 Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012 0.81
33 Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Ann Oncol 2015 0.80
34 Research in castration-resistant prostate cancer: what does the future hold? Curr Oncol 2010 0.79
35 New insights into the androgen-targeted therapies and epigenetic therapies in prostate cancer. Prostate Cancer 2011 0.79
36 Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol 2011 0.78
37 Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer. Drug Discov Today Ther Strateg 2010 0.76
38 Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report. Oncol Lett 2013 0.75
39 Prostate cancer: Age is nothing but a number. Nat Rev Urol 2013 0.75
40 Abiraterone acetate. Drugs R D 2010 0.75
41 The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 2013 0.75
42 Abiraterone acetate, an inhibitor of adrenal androgen synthesis in "hormone refractory prostate cancer". Indian J Med Paediatr Oncol 2011 0.75
43 High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. Eur J Cancer 2015 0.75
Next 100